Alumis Inc., a clinical-stage biopharmaceutical company, announced an update on its merger agreement with ACELYRIN, Inc. On May 13, 2025, Alumis stockholders approved all proposals related to the pending merger during a Special Meeting of Stockholders. The merger, slated for completion in the second quarter of 2025, aims to enhance value creation opportunities for both companies' stockholders. The amended agreement stipulates that ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock per ACELYRIN share. Post-merger, Alumis stockholders will hold approximately 52% of the combined entity, while ACELYRIN stockholders will own around 48% on a fully diluted basis. The merger is expected to advance a differentiated clinical pipeline and provide financial flexibility for strategic opportunities in immune-mediated diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.